Indeed, the MDA-MB-231.CCR5−/− cells are more sensitive to inhibitors blocking glucose uptake and glutamine catabolism and have a lower proliferation rate than MDA-MB-231.CCR5+/+ cells, in further support of a role for CCL5 activation of CCR5 contributing to tumor cell metabolism. Here, CCR5 is linked to neoplasm.